Similar articles

• Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.

  Kanal E, Broome DR, Martin DR, Thomsen HS. Kanal E, et al. Radiology. 2008 Jan;246(1):11-4. doi: 10.1148/radiol.2461071267. Epub 2007 Sep 12. Radiology. 2008. PMID: 17855656 No abstract available.
• Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.

  Tsushima Y, Takahashi-Taketomi A, Endo K. Tsushima Y, et al. Radiology. 2008 Jun;247(3):915-6. doi: 10.1148/radiol.2473072101. Radiology. 2008. PMID: 18487548 No abstract available.
• Safety of magnetic resonance imaging contrast agents.

  Shellock FG, Kanal E. Shellock FG, et al. J Magn Reson Imaging. 1999 Sep;10(3):477-84. doi: 10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e. J Magn Reson Imaging. 1999. PMID: 10508312 Review.
• [The Grenelle of MR contrast agents?].

  Clément O. Clément O. J Radiol. 2007 Nov;88(11 Pt 1):1663. doi: 10.1016/s0221-0363(07)74043-x. J Radiol. 2007. PMID: 18065924 French. No abstract available.
• MR contrast enhancement of intracranial lesions with Gd-DTPA.

  Hesselink JR, Press GA. Hesselink JR, et al. Radiol Clin North Am. 1988 Jul;26(4):873-87. Radiol Clin North Am. 1988. PMID: 3289078 Review.